TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04000737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YIV-906+Sorafenib
Description: Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo+Sorafenib
Description: Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
Study: NCT02049840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Altis Single Incision Sling System
Description: Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
Study: NCT02994459

Intervention type: OTHER
Intervention: Weight Loss
Description: Diet-induced weight loss (obese only)

Intervention type: OTHER
Intervention: Weight Loss
Description: Diet-induced weight loss (obese only)
Study: NCT02174913

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bispectral index
Description: Bispectral index (BIS) is one of several technologies used to monitor depth of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Target controlled infusion of propofol
Description: TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Target controlled infusion of propofol
Description: TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Description: Atracurium 0.6 mg/kg is used for endotracheal intubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atracurium
Description: Atracurium 0.6 mg/kg is used for endotracheal intubation
Study: NCT04658524

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid function
Description: laboratorial thyroid tests
Study: NCT01173055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran
Description: Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given orally twice daily in tablet form at different times during the course of the study.
Study: NCT02083185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: Leuprorelin subcutaneous injection
Study: NCT02406300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subarachnoid Anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNB/GA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane or desflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine or levobupivacaine
Study: NCT03754634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag and Diacerein
Description: The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
Study: NCT01117233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 10 mg PF-04427429 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 30 mg PF-04427429 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 100 mg PF-04427429 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 300 mg PF-04427429 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 1000 mg PF-04427429 or placebo
Study: NCT02319720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Bone Marrow Cells
Description: The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Bone Marrow Cells
Description: The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
Study: NCT01157650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: The trial is divided in three phases:~I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.~II.- Treatment phase includes:~1. Liposuction procedure to obtain adipose tissue.~2. Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)~3. ASCs implant~III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant.
Study: NCT04303533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-Feedback EFP
Description: Neurofeedback (NF) - is a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Amygdala-EFP (EEG-finger-print, EFP) is an EEG-NF application that modulates amygdala response.
Study: NCT01588457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex
Description: DV will be dosed to attain DV levels of ≥45mg/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex
Description: DV will be dosed to attain DV levels of ≥45mg/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex
Description: DV will be dosed to attain DV levels of ≥45mg/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
Study: NCT04738422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkaline glycine
Description: Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
Study: NCT04601103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No SLS toothpaste
Description: Toothpaste no Sodium Lauryl Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium SLS toothpaste
Description: Less than or equal to X ppm Sodium Lauryl Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High SLS toothpaste
Description: More than or equal to X ppm Sodium Lauryl Sulfate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-plaque
Description: Rinse prevents bacterial adherence to teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-plaque
Description: Rinse prevents bacterial adherence to teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-plaque
Description: Rinse prevents bacterial adherence to teeth
Study: NCT03164473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: oral tablets : 2 mg/kg/day for 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-rituximab
Description: 4 infusions for 18 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-azathioprine
Description: oral tablets for 24 months
Study: NCT05454540

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS
Study: NCT03655678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX001
Description: Administered by IV infusion following myeloablative conditioning with busulfan
Study: NCT02289781

Intervention type: DEVICE
Intervention: posterior crowns
Description: teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material

Intervention type: DEVICE
Intervention: posterior crowns
Description: teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
Study: NCT03165006

Intervention type: PROCEDURE
Intervention: Mode of detection: Cancer detected at screening
Description: Cancers detected as a result of screening mammograms.

Intervention type: PROCEDURE
Intervention: Mode of detection: Interval cancer
Description: Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
Study: NCT02941068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole and caspofungin
Study: NCT03039543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
Study: NCT02572817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-titer anti-influenza plasma
Description: Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-titer anti-influenza plasma
Description: Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
Study: NCT00863889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depomedrol injection
Description: 1 cc of Depomedrol 80

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine, Marcaine
Description: 4 cc of each local anesthetic
Study: NCT03524456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Description: Participants would use a blood pressure device at home, that sends the readings automatically to the health center via SMS. The physicians would use this tool for medication management or rescheduling visits.
Study: NCT00822003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral GLP-1
Description: GLP-1 tablet (2mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control tablet
Study: NCT01447849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lubiprostone
Description: 24mcg twice a day (BID) 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pills twice a day for one week.
Study: NCT02364232

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: bilateral training with and without mirror feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bilateral training with and without mirror feedback
Study: NCT01136889

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.
Study: NCT02641886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jian Pi Yi Shen Hua Tan Granules
Description: Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the placebo group
Description: Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
Study: NCT03203226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FELDENKRAIS METHOD (FM)
Description: They EG will receive the intervention of FM consisting of 30 lessons (1h-lesson per week; 30 weeks) verbal instructions provided by the therapist to participants. These instructions provide different options on how to perform a specific task with the purpose of leaving the decision on how to do the movement up to the performer, who has to focus on thinking, feeling, sensing and doing the movement as easily as possible.The lessons can be conducted sitting, standing or moving within a room.
Study: NCT01167049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPECITABINE
Description: Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
Study: NCT02897726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1402
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1402R
Description: Oral
Study: NCT02594189

Intervention type: OTHER
Group type: OTHER
Intervention: Live recombinantly derived A/Bethesda/MM1/H3N2 virus
Description: The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
Study: NCT02004821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.
Study: NCT02956369

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control granulates (maize starch and long-chain fatty acids) with powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SATIOSTAT
Description: SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder
Study: NCT03105986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575
Description: Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575
Description: Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
Study: NCT01489124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: 0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: 0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: 1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Study: NCT02101372

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: case management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation group treatment
Description: Psychoeducation therapy problem solving focus
Study: NCT03338803

Intervention type: DRUG
Intervention: Linagliptin
Description: drug
Study: NCT00828724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10mg
Study: NCT04458025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation program
Description: Standard rehabilitation will start 4 weeks after surgery according to the standard of cre

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early rehabilitation program
Description: Early rehabilitation program will start 2 weeks